A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas

por Lee, J K, Capanu, M, O'Reilly, E M, Ma, J, Chou, J F, Shia, J, Katz, S S, Gansukh, B, Reidy-Lagunes, D, Segal, N H, Yu, K H, Chung, K-Y, Saltz, L B, Abou-Alfa, G K
Publicado 2013

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

por Ducreux, M., Abou-Alfa, G.K., Bekaii-Saab, T., Berlin, J., Cervantes, A., de Baere, T., Eng, C., Galle, P., Gill, S., Gruenberger, T., Haustermans, K., Lamarca, A., Laurent-Puig, P., Llovet, J.M., Lordick, F., Macarulla, T., Mukherji, D., Muro, K., Obermannova, R., O’Connor, J.-M., O’Reilly, E.M., Osterlund, P., Philip, P., Prager, G., Ruiz-Garcia, E., Sangro, B., Seufferlein, T., Tabernero, J., Verslype, C., Wasan, H., Van Cutsem, E.
Publicado 2023